Melding genetics and code, BigHat Biosciences is a protein therapeutics company that develops antibodies for the medical industry using machine learning and AI. Established in 2019, the company combines advanced computational models with an automated wet lab to design and test antibody therapies more quickly than traditional methods. Its technology has been applied to a range of use cases too, including efforts during the pandemic to accelerate vaccine and therapeutic development.
The platform has particular value in helping develop treatment for complex and hard-to-treat diseases such as Alzheimer's disease, where designing effective biologic drugs is especially challenging. To support this work, BigHat has partnered with major pharmaceutical companies including Merck & Co, and Amgen to apply its AI-driven antibody design platform to drug discovery and development.
More recently, BigHat has continued to expand its partnerships and pipeline as interest in AI-enabled drug discovery grows. The company has also collaborated with Eli Lilly and Company to help develop next-generation antibody therapeutics using its Milliner platform, while also advancing its own internal programmes in areas such as oncology. With candidates including a gastrointestinal cancer and antibody-drug conjugate expected to enter clinical trials in 2026, BigHat is positioning itself not only as a technology partner for pharmaceutical companies but as as developer of its own next-generation biologic medicines.
Kirsty
Company Specialist at Welcome to the Jungle
